Chlorpromazine Hydrochloride

盐酸氯丙嗪

Report date: 2026/03/17 20:00:15
NME

Base Information

Drug NameChlorpromazine Hydrochloride
Drug Alias Name冬眠灵Chlorpromazine冬眠硫磷Chlorpromazinum盐酸氯普鲁马嗪 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors antagonists
TargetsDopamine receptors
Therapy Area/IndicationsSedationCoronavirus Disease 2019 (COVID-19)Hypnosis +[17] 
Global Approved IndicationsSedationHypnosisSchizophrenia +[13] 
Approved Indications in ChinaSchizophreniaBipolar DisorderVomiting
Original Approved Country/TerritoryJapan
Original Approved Date1955/04/01
Country/TerritoryUnited StatesSouth AfricaEgypt +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesMitsubishi Tanabe PharmaChangzhou Kangpu Pharmaceutical Co Ltd
Inactive CompaniesWhanin Pharmaceutical CompanyCycle Pharmaceuticals LtdGlaxosmithkline Plc +[5] 
Active IndicationsSedationHypnosisSchizophrenia +[12] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Mental DisordersSigns and Symptoms, Digestive +[5] 

Other Information

ATC CodeN05AA01
Related LinksWikipediaDrugBankKEGG